AZN.UK

10,220

-1.45%↓

GSK

1,397

-0.64%↓

INDV

1,148

+3.24%↑

AZN.UK

10,220

-1.45%↓

GSK

1,397

-0.64%↓

INDV

1,148

+3.24%↑

AZN.UK

10,220

-1.45%↓

GSK

1,397

-0.64%↓

INDV

1,148

+3.24%↑

AZN.UK

10,220

-1.45%↓

GSK

1,397

-0.64%↓

INDV

1,148

+3.24%↑

AZN.UK

10,220

-1.45%↓

GSK

1,397

-0.64%↓

INDV

1,148

+3.24%↑

Search

PureTech Health Plc

Cerrado

127.8 0.63

Resumen

Variación precio

24h

Actual

Mínimo

125.2

Máximo

129.8

Métricas clave

By Trading Economics

Ingresos

70M

Ventas

4M

P/B

Media del Sector

8.307

40.527

Margen de beneficio

1,727.216

Empleados

56

EBITDA

102M

Dividendos

By Dow Jones

Próximas Ganancias

27 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

299M

Apertura anterior

127.17

Cierre anterior

127.8

PureTech Health Plc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

6 jul 2025, 23:55 UTC

Charlas de Mercado

Gold Edges Lower on Possible Position Adjustments -- Market Talk

6 jul 2025, 22:35 UTC

Adquisiciones, fusiones, absorciones

South32 Expects to Complete Transaction in Late 2025

6 jul 2025, 22:35 UTC

Adquisiciones, fusiones, absorciones

South32: CoreX to Make Future Cash Payments of Up to US$100 Million for Cerro Matoso

6 jul 2025, 22:34 UTC

Adquisiciones, fusiones, absorciones

South32 Agrees to Sell Cerro Matoso Nickel Operation to Unit of CoreX Holding

5 jul 2025, 04:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

4 jul 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

4 jul 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

4 jul 2025, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

4 jul 2025, 20:50 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

4 jul 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

4 jul 2025, 16:20 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

4 jul 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

4 jul 2025, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

4 jul 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

4 jul 2025, 15:57 UTC

Charlas de Mercado

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 jul 2025, 15:49 UTC

Charlas de Mercado

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 jul 2025, 15:49 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 jul 2025, 15:49 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 jul 2025, 15:49 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole Received All Required Authorizations

4 jul 2025, 15:48 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 jul 2025, 15:47 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole: Agreement Was Announced on Dec. 19

4 jul 2025, 15:47 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 jul 2025, 15:46 UTC

Adquisiciones, fusiones, absorciones

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 jul 2025, 14:30 UTC

Adquisiciones, fusiones, absorciones

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 jul 2025, 13:53 UTC

Charlas de Mercado

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 jul 2025, 13:41 UTC

Charlas de Mercado

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 jul 2025, 13:41 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

4 jul 2025, 13:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

4 jul 2025, 12:37 UTC

Charlas de Mercado

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 jul 2025, 12:37 UTC

Charlas de Mercado

Fund Manager Roundup: U.S. Treasurys in Focus -2-

Comparación entre iguales

Cambio de precio

PureTech Health Plc Esperado

Consenso

By TipRanks

0 ratings

0

Comprar

0

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de PureTech Health Plc

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.